Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV.

Publication date: Nov 15, 2024

In this prospective longitudinal study, we evaluated the durability of humoral responses to SARS-CoV-2 mRNA booster vaccination in 93 people with HIV, exploring the possible role of T-cell dysfunction and inflammaging biomarkers in predicting antibody waning. We found that, despite a negligible influence of the inflammaging milieu, low CD4/CD8 ratio and CD4+CD127+ percentage as well as high CD8+CD38+CD45RO+ percentage are associated with faster antibody waning, in turn contributing to our understanding of the determinants of COVID-19 vaccine-elicited immune response in this population.

Concepts Keywords
Biomarkers Adult
Cd45ro Antibodies, Viral
Durability Antibodies, Viral
Hiv Biomarkers
Vaccination Biomarkers
CD4-CD8 Ratio
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
HIV Infections
Humans
Immunity, Humoral
Immunization, Secondary
Longitudinal Studies
Male
Middle Aged
Prospective Studies
SARS-CoV-2
T-Lymphocytes

Semantics

Type Source Name
disease IDO cell
disease IDO role
disease IDO immune response
disease MESH COVID-19
disease MESH HIV Infections

Original Article

(Visited 1 times, 1 visits today)